NCT06488586 IV Ketamine vs. IN Esketamine for MDD TRD
| NCT ID | NCT06488586 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Gustavo Vazquez |
| Condition | Treatment Resistant Depression |
| Study Type | OBSERVATIONAL |
| Enrollment | 80 participants |
| Start Date | 2023-03-20 |
| Primary Completion | 2026-03-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 80 participants in total. It began in 2023-03-20 with a primary completion date of 2026-03-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn about the comparative acute effects of ketamine vs esketamine in participants over the age of 18 for the treatment of their severe depression and suicidal ideations. Participants are already taking antidepressants and/or antipsychotics as part of their regular medical care for depression,
Eligibility Criteria
Inclusion Criteria: * Adult outpatients (18-75 years old) with unipolar depression experiencing major depressive episodes as determined by the DSM5 and characterized as MDD-TRD (diagnosed with major depressive disorder as outlined by the DSM5) and experienced at least two previous failed antidepressant treatments of adequate dose and duration for the current episode Exclusion Criteria: * Individuals with psychosis, main diagnosis of personality disorder, uncontrolled hypertension, substance abuse, currently pregnant or breastfeeding, or who had a previous negative reaction to ketamine or esketamine, were ineligible to receive IV ketamine or IN esketamine.
Contact & Investigator
Gustavo H Vazquez, MD,PhD,FRCPC
PRINCIPAL INVESTIGATOR
Queen's University
Frequently Asked Questions
Who can join the NCT06488586 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Treatment Resistant Depression. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06488586 currently recruiting?
Yes, NCT06488586 is actively recruiting participants. Contact the research team at g.vazquez@queensu.ca for enrollment information.
Where is the NCT06488586 trial being conducted?
This trial is being conducted at Kingston, Canada.
Who is sponsoring the NCT06488586 clinical trial?
NCT06488586 is sponsored by Gustavo Vazquez. The principal investigator is Gustavo H Vazquez, MD,PhD,FRCPC at Queen's University. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.